Live biotherapeutic products (LBPs) have been hailed as the answer for patients suffering from Irritable Bowel Syndrome (IBS), says GlobalData, which cite a lack of defined regulations as the main barrier to progress.
‘Designer’ biotherapeutics rationally designed to address the dysbiotic microbiome seen in Crohn’s disease and ulcerative colitis may be the ‘breakthrough’ researchers are looking for in tackling these conditions.
Newly formed NovoBiome becomes the latest firm to delve into the gut microbiome as it aims to harness Artificial Intelligence (AI) to develop Live Biotherapeutic Products (LBPs) that address liver conditions.
There is an urgent need for clarification of concepts and constraints of the probiotics used in Live Biotherapeutic (LBP) products with success dependent on credible safety and efficacy demonstrations, says a European authority.
New recommendations that address the safety of biological products containing live microorganisms, may help firms obtain a marketing authorisation that is so far proving elusive, according to a research team